Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VLTS-589
- Development stage
- Unknown
- Lead developer
- Urigen Pharmaceuticals
- Modality
- Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Lipid-mediated Delivery → Gene Addition/Replacement → Gene Therapies, Electrical: Electroporation → Physical Methods → Gene Addition/Replacement → Gene Therapies, Mechanical: Microinjection, microfluidics, gene gun → Physical Methods → Gene Addition/Replacement → Gene Therapies, Acoustic/Optical: Sonoporation, laser photoporation → Physical Methods → Gene Addition/Replacement → Gene Therapies, Pressure-driven: Hydrodynamic injection → Physical Methods → Gene Addition/Replacement → Gene Therapies, Magnetic: Magnetofection → Physical Methods → Gene Addition/Replacement → Gene Therapies
- Administration
- Intramuscular
01
Overview
VLTS-589 is an investigational nonviral gene therapy designed for the treatment of peripheral vascular disease, specifically targeting intermittent claudication in patients with peripheral arterial disease. The drug consists of a plasmid encoding the angiomatrix protein Del-1 (developmentally regulated endothelial locus 1), formulated with poloxamer 188 to enhance gene transfer and transfection efficiency. Delivered via multiple intramuscular injections to both lower extremities, VLTS-589 aims to induce angiogenesis and arteriogenesis by promoting new blood vessel growth in ischemic tissues. Clinical studies have evaluated its safety and efficacy in improving exercise capacity (peak walking time), claudication onset time, ankle brachial index, and quality of life measures compared to baseline[1][3][4][5][8]. Developed by Valentis, this approach represents one of the largest plasmid-based gene transfer trials for therapeutic angiogenesis in peripheral artery disease.
- Other names
- Valentis
02
Targets
CD36 (CD36 antigen)αVβ3 (Integrin αVβ3)OLR1 (Lectin-like oxidized LDL receptor-1)NeuraminidaseMSR1 (Amyloid beta precursor protein binding family B member 3)SCARB1 (Scavenger receptor class B member 1)DEL-1 (EGF-like repeat and discoidin I-like domain-containing protein 3 (EDIL3))
Beyond the preview
Go deeper on VLTS-589.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VLTS-589.